X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (12752) 12752
Book Review (1248) 1248
Publication (982) 982
Newsletter (47) 47
Magazine Article (29) 29
Book Chapter (18) 18
Transcript (12) 12
Dissertation (11) 11
Newspaper Article (10) 10
Book / eBook (8) 8
Conference Proceeding (7) 7
Trade Publication Article (4) 4
Paper (2) 2
Government Document (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (11655) 11655
humans (8550) 8550
male (6808) 6808
sulfonamides - administration & dosage (5354) 5354
animals (5199) 5199
female (4935) 4935
sulfonamides - pharmacology (4066) 4066
sulfonamides - therapeutic use (3922) 3922
middle aged (3241) 3241
pharmacology & pharmacy (2740) 2740
adult (2735) 2735
aged (2411) 2411
sulfonamides - adverse effects (2265) 2265
rats (2190) 2190
treatment outcome (1833) 1833
mice (1737) 1737
celecoxib (1697) 1697
dose-response relationship, drug (1631) 1631
oncology (1376) 1376
sulfonamides (1330) 1330
abridged index medicus (1287) 1287
sulfonamides - pharmacokinetics (1267) 1267
drug therapy, combination (1244) 1244
administration, oral (1093) 1093
analysis (1039) 1039
drug therapy (1014) 1014
time factors (947) 947
care and treatment (899) 899
double-blind method (895) 895
research (892) 892
rats, sprague-dawley (879) 879
cancer (871) 871
rosuvastatin calcium (818) 818
expression (811) 811
pyrimidines - administration & dosage (790) 790
disease models, animal (776) 776
dosage and administration (767) 767
therapy (766) 766
pharmacokinetics (734) 734
aged, 80 and over (733) 733
cardiac & cardiovascular systems (720) 720
medicine & public health (711) 711
drug administration schedule (706) 706
pyrimidines - therapeutic use (687) 687
adolescent (677) 677
cell line, tumor (675) 675
sulfonamides - chemistry (667) 667
efficacy (661) 661
rats, wistar (644) 644
apoptosis (637) 637
pyrazoles - administration & dosage (633) 633
prospective studies (606) 606
health aspects (605) 605
safety (564) 564
drug interactions (558) 558
neurosciences (558) 558
biochemistry & molecular biology (555) 555
medicine, general & internal (541) 541
pyrazoles - pharmacology (530) 530
cyclooxygenase inhibitors - pharmacology (506) 506
nonsteroidal antiinflammatory drugs (505) 505
article (496) 496
pharmacology/toxicology (494) 494
sulfonamides - blood (494) 494
apoptosis - drug effects (489) 489
inflammation (487) 487
drugs (486) 486
young adult (486) 486
clinical trials (481) 481
risk factors (467) 467
cox-2 inhibitors (460) 460
pharmacology (460) 460
pyrazoles - therapeutic use (457) 457
dogs (451) 451
chemistry, medicinal (448) 448
in-vitro (444) 444
drug synergism (440) 440
hypertension (433) 433
cyclooxygenase 2 (432) 432
bosentan (428) 428
rosuvastatin (427) 427
double-blind (426) 426
cells (419) 419
fluorobenzenes - administration & dosage (419) 419
ophthalmology (419) 419
internal medicine (416) 416
antineoplastic combined chemotherapy protocols - therapeutic use (414) 414
follow-up studies (412) 412
hiv infections - drug therapy (410) 410
cyclooxygenase-2 (408) 408
medicine, research & experimental (400) 400
intraocular pressure - drug effects (398) 398
cell biology (395) 395
indoles - administration & dosage (394) 394
drug combinations (392) 392
immunology (392) 392
antihypertensive agents - administration & dosage (389) 389
clinical trials as topic (388) 388
inhibition (387) 387
cyclooxygenase 2 inhibitors (386) 386
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (12230) 12230
German (149) 149
French (109) 109
Russian (97) 97
Japanese (90) 90
Italian (35) 35
Spanish (35) 35
Chinese (30) 30
Hungarian (13) 13
Romanian (12) 12
Polish (11) 11
Danish (9) 9
Norwegian (7) 7
Czech (6) 6
Dutch (6) 6
Slovak (6) 6
Swedish (6) 6
Bulgarian (5) 5
Portuguese (4) 4
Turkish (4) 4
Croatian (3) 3
Hebrew (2) 2
Ukrainian (2) 2
Korean (1) 1
Lithuanian (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Gastroenterology, ISSN 0016-5085, 2016, Volume 151, Issue 3, pp. 457 - 471.e5
Journal Article
Gastroenterology, ISSN 0016-5085, 2016, Volume 150, Issue 7, pp. 1590 - 1598
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 08/2015, Volume 21, Issue 16, pp. 3705 - 3715
Purpose: Bruton's tyrosine kinase (BTK) is a critical enzyme in the B-cell receptor pathway and is inhibited by ibrutinib due to covalent binding to the kinase... 
B-CELL RECEPTOR | TUMOR PROLIFERATION | BRUTONS TYROSINE KINASE | CLL | ONCOLOGY | BCL-2 INHIBITOR | INITIAL THERAPY | IN-VIVO | PCI-32765 | KINASE INHIBITOR IBRUTINIB | SINGLE-ARM | Piperazines - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Apoptosis - drug effects | Humans | Neoplastic Cells, Circulating - metabolism | Male | Leukemia, Lymphocytic, Chronic, B-Cell - genetics | Purines - administration & dosage | Bendamustine Hydrochloride - administration & dosage | Protein-Tyrosine Kinases - genetics | Female | bcl-X Protein - biosynthesis | Protein-Tyrosine Kinases - biosynthesis | B-Cell Activating Factor - biosynthesis | Neoplastic Cells, Circulating - drug effects | Pyrimidines - administration & dosage | Gene Expression Regulation, Leukemic - drug effects | Nitrophenols - administration & dosage | Bridged Bicyclo Compounds, Heterocyclic - administration & dosage | Proto-Oncogene Proteins c-bcl-2 - biosynthesis | Leukemia, Lymphocytic, Chronic, B-Cell - pathology | Pyrazoles - administration & dosage | B-Cell Activating Factor - genetics | Biphenyl Compounds - administration & dosage | Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Isoquinolines - administration & dosage | Proto-Oncogene Proteins c-bcl-2 - genetics | Sulfonamides - administration & dosage | Index Medicus
Journal Article
Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9829, pp. 1893 - 1901
Summary Background Dabrafenib is an inhibitor of BRAF kinase that is selective for mutant BRAF. We aimed to assess its safety and tolerability and to establish... 
Internal Medicine | SURVIVAL | IRRADIATION | MEDICINE, GENERAL & INTERNAL | PATHWAY | RAF INHIBITOR RESISTANCE | B-RAF | MUTATIONS | CANCER | BRAF(V600E) | VEMURAFENIB | Oximes - adverse effects | Humans | Middle Aged | Carcinoma, Squamous Cell - chemically induced | Oximes - administration & dosage | Imidazoles - administration & dosage | Male | Fatigue - chemically induced | Antineoplastic Agents - administration & dosage | Fever - chemically induced | Indoles - administration & dosage | Brain Neoplasms - secondary | Neoplasms - genetics | Antineoplastic Agents - adverse effects | Melanoma - genetics | Adult | Female | Drug Administration Schedule | Imidazoles - adverse effects | Genotype | Treatment Outcome | Skin Neoplasms - chemically induced | Brain Neoplasms - drug therapy | Mutation - genetics | Melanoma - secondary | Neoplasms - drug therapy | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Maximum Tolerated Dose | Indoles - adverse effects | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Sulfonamides - adverse effects | Sulfonamides - administration & dosage | Antimitotic agents | Complications and side effects | Melanoma | Dosage and administration | Metastasis | Antineoplastic agents | Drug therapy | Clinical trials | Medical research | Chemotherapy | Mutation | Toxicity | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
JAMA, ISSN 0098-7484, 05/2014, Volume 311, Issue 18, pp. 1870 - 1882
Journal Article
JAMA, ISSN 0098-7484, 03/2015, Volume 313, Issue 12, pp. 1223 - 1231
Journal Article
Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9941, pp. 403 - 413
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2017, Volume 66, Issue 6, pp. 1138 - 1148
Graphical abstract 
Gastroenterology and Hepatology | Antiviral agents | Ombitasvir | Ritonavir | Ledipasvir | Real-world | Genotype 1 | Paritaprevir | Sustained virologic response | Hepatitis C, Chronic | Sofosbuvir | Dasabuvir | Randomized controlled trials | PLUS RIBAVIRIN | VIRUS-INFECTION | CHRONIC HEPATITIS-C | SUSTAINED VIROLOGICAL RESPONSE | ALL-CAUSE MORTALITY | Chronic | HEPATOCELLULAR-CARCINOMA | TREATMENT-EXPERIENCED PATIENTS | Hepatitis C | GASTROENTEROLOGY & HEPATOLOGY | Uridine Monophosphate - administration & dosage | Humans | Middle Aged | Hepatitis C, Chronic - physiopathology | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Carbamates - administration & dosage | Neoplasm Recurrence, Local - etiology | Liver Neoplasms - etiology | Young Adult | Uracil - administration & dosage | Benzimidazoles - administration & dosage | Ribavirin - administration & dosage | Aged, 80 and over | Adult | Female | Fluorenes - administration & dosage | Carcinoma, Hepatocellular - etiology | Retrospective Studies | Drug Therapy, Combination | Glomerular Filtration Rate | Ritonavir - administration & dosage | Antiviral Agents - therapeutic use | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Spain | Anilides - administration & dosage | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Aged | Macrocyclic Compounds - administration & dosage | Sustained Virologic Response | Sulfonamides - administration & dosage | Cohort Studies | Uracil - analogs & derivatives | Genetic aspects | Safety and security measures | Hepatitis C virus | Clinical trials | Chronic infection | Data processing | Hepatocellular carcinoma | Multivariate analysis | Patients | Clinical outcomes | Ribavirin | Genotype & phenotype | Cohort analysis | Fibrosis | Safety | Drug therapy | Antiviral drugs | Genotypes | Index Medicus
Journal Article